Diabetic Neuropathies Clinical Trial
Official title:
A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain
Verified date | January 2013 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.
Status | Completed |
Enrollment | 280 |
Est. completion date | October 2008 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - If female, subject is either postmenopausal for at least two (2) years or surgically sterile or is practicing at least one (1) method of birth control. - If female, subject must have negative results for pregnancy tests. - The subject must have a diagnosis of diabetes mellitus (Type 1 or Type 2) and a diagnosis of DNP. - Subject's DNP must be present for a minimum of six (6) months and should have begun in the feet with relative symmetrical onset. - Subject has an HgbA1c <= 9. Subjects who have an HgbA1c > 9 and <= 11 may be included in the study. - If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method (condom) of birth control for the duration of the study and for 7 days following the last dose of study drug. Exclusion Criteria: - The subject has failed previous treatment with duloxetine for DNP. - Subject has a diagnosis of narrow-angle glaucoma. - Subject has a history of an allergic reaction or intolerance to duloxetine, acetaminophen, or any other NNR agonist. - Subject has a diagnosis of fibromyalgia that requires treatment. - Subject has a functioning implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain. - Subject has a history of seizures (febrile may be ok) or major depressive episode within the past two (2) years or major psychiatric disorder including bipolar disorder, schizophrenia or borderline personality disorder. - Subject has a history of myocardial infarction (MI) within six (6) months of the Screening Visit. - Subject has unstable angina. - Subject has ventricular arrhythmia requiring anti-arrhythmic therapy. - Subject has undergone a cardiac revascularization procedure within 30 days of Screening. - Subject has uncontrolled hypertension (HTN) defined as a systolic blood pressure (BP) >= 160 and/or a diastolic blood pressure (BP) >= 100 at Screening and/or Baseline. - Subject has a clinically significant abnormal ECG at Screening - Subject has an active malignancy of any type or has been diagnosed with or treated for cancer within the past 5 years. - Subject has a positive result for drugs of abuse at Screening with the exception of a positive result for a known prescribed medication. - Subject's screening laboratory results show hepatitis A, B or C. - Subject has a known or suspected history of Human Immunodeficiency Virus (HIV). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Site Reference ID/Investigator# 8508 | Kingston | |
Canada | Site Reference ID/Investigator# 8436 | Laval | |
Canada | Site Reference ID/Investigator# 8481 | Winnipeg | |
France | Site Reference ID/Investigator# 5258 | Corbeil Essonnes | |
France | Site Reference ID/Investigator# 7696 | Nanterre | |
France | Site Reference ID/Investigator# 5260 | Narbonne | |
France | Site Reference ID/Investigator# 5171 | Nevers | |
France | Site Reference ID/Investigator# 7115 | Nimes | |
Germany | Site Reference ID/Investigator# 6763 | Berlin | |
Germany | Site Reference ID/Investigator# 7117 | Essen | |
Germany | Site Reference ID/Investigator# 5034 | Frankfurt | |
Germany | Site Reference ID/Investigator# 6760 | Heidelberg | |
Germany | Site Reference ID/Investigator# 6732 | Mainz | |
Italy | Site Reference ID/Investigator# 5018 | Milan | |
Italy | Site Reference ID/Investigator# 5006 | Rome | |
Mexico | Site Reference ID/Investigator# 8427 | Guadalajara | |
Mexico | Site Reference ID/Investigator# 8497 | Mexico D.F. | |
Mexico | Site Reference ID/Investigator# 8125 | Monterrey, N.L. | |
Puerto Rico | Site Reference ID/Investigator# 8120 | Ponce | |
Puerto Rico | Site Reference ID/Investigator# 8121 | San Juan | |
United States | Site Reference ID/Investigator# 6052 | Anaheim | California |
United States | Site Reference ID/Investigator# 5277 | Brockton | Massachusetts |
United States | Site Reference ID/Investigator# 5947 | Cincinnati | Ohio |
United States | Site Reference ID/Investigator# 5276 | Clearwater | Florida |
United States | Site Reference ID/Investigator# 6869 | Cuyahoga Falls | Ohio |
United States | Site Reference ID/Investigator# 7064 | Garden Grove | California |
United States | Site Reference ID/Investigator# 6781 | Hialeah | Florida |
United States | Site Reference ID/Investigator# 7699 | Houston | Texas |
United States | Site Reference ID/Investigator# 5206 | Little Rock | Arkansas |
United States | Site Reference ID/Investigator# 5207 | Mesa | Arizona |
United States | Site Reference ID/Investigator# 8286 | National City | California |
United States | Site Reference ID/Investigator# 5216 | New York | New York |
United States | Site Reference ID/Investigator# 5946 | New York | New York |
United States | Site Reference ID/Investigator# 6045 | New York | New York |
United States | Site Reference ID/Investigator# 7483 | New York | New York |
United States | Site Reference ID/Investigator# 7387 | North Little Rock | Arkansas |
United States | Site Reference ID/Investigator# 7906 | Omaha | Nebraska |
United States | Site Reference ID/Investigator# 7514 | Palm Beach Gardens | Florida |
United States | Site Reference ID/Investigator# 6047 | Pasadena | Maryland |
United States | Site Reference ID/Investigator# 6053 | Phoenix | Arizona |
United States | Site Reference ID/Investigator# 5217 | Portland | Oregon |
United States | Site Reference ID/Investigator# 5836 | San Antonio | Texas |
United States | Site Reference ID/Investigator# 5899 | San Antonio | Texas |
United States | Site Reference ID/Investigator# 5950 | San Antonio | Texas |
United States | Site Reference ID/Investigator# 7187 | San Antonio | Texas |
United States | Site Reference ID/Investigator# 6054 | Seattle | Washington |
United States | Site Reference ID/Investigator# 6043 | St. Louis | Missouri |
United States | Site Reference ID/Investigator# 6044 | St. Louis | Missouri |
United States | Site Reference ID/Investigator# 8113 | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) |
United States, Canada, France, Germany, Italy, Mexico, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP | Change from baseline to final 24-hour average pain score | No | |
Secondary | Proportions of treatment responders; subjects who complete treatment period with 30% improvement | From Baseline to final 24-hour average pain score | No | |
Secondary | Mean of 24-hour worst pain severity, average of night pain, and average of morning pain measured by the 11-point Likert scale and from subject's daily diary | Weekly through treatment phase | No | |
Secondary | Brief Pain Inventory (BPI) (short form) including Pain Severity | At each visit from Baseline to Week 8 visit | No | |
Secondary | Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C) | At each visit from Baseline to Week 8 visit | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05683106 -
Effects of Customized Silicone Digital Orthoses in People With Diabetic Neuropathy
|
N/A | |
Withdrawn |
NCT04106050 -
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
|
Phase 1 | |
Completed |
NCT04088929 -
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT01939366 -
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
|
Phase 2 | |
Withdrawn |
NCT00815932 -
The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy
|
N/A | |
Completed |
NCT01926522 -
Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients
|
N/A | |
Not yet recruiting |
NCT01180608 -
Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain
|
N/A | |
Completed |
NCT00380913 -
Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy
|
Phase 4 | |
Completed |
NCT00760955 -
Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Terminated |
NCT00756041 -
Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT05255497 -
The Effect of Sensorial Biodex Balance Balance System Exercises in Diabetic Neuropathy
|
N/A | |
Completed |
NCT06061237 -
Effects of Aerobic Thai Dance in Patient With Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT02915263 -
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
|
Phase 2 | |
Enrolling by invitation |
NCT05043636 -
Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
|
||
Completed |
NCT06373809 -
Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy
|
Early Phase 1 | |
Completed |
NCT05968131 -
Comparative Effects of Proprioceptive Training and Routine Physical Therapy on Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00282685 -
Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy
|
Phase 1 | |
Completed |
NCT00135109 -
Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT06292962 -
Evaluating the Impact of Vagus Nerve Stimulation on Diabetic Peripheral Neuropathic Pain
|
N/A | |
Completed |
NCT05058807 -
Effects of Whole Body Vibration in Diabetic Peripheral Neuropathy .
|
N/A |